Trinity Biotech (TRIB) Depreciation & Amortization (CF) (2009 - 2024)

Trinity Biotech (TRIB) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $317000.0 the latest figure, recorded in Q4 2024.

• Quarterly Depreciation & Amortization (CF) rose 15750.0% year-over-year to $317000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $317260.0 (changed 0.03% YoY) and the FY2025 annual result came in at $1.3 million, up 92.44% from the prior year.
• Depreciation & Amortization (CF) climbed to $317000.0 in Q4 2024 per TRIB's latest filing, from $260.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for TRIB reached as high as $478000.0 in Q3 2022 and fell as low as -$65.0 in Q2 2024.
• A 4-year average of $107524.0 and a median of $351.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The largest YoY upside for Depreciation & Amortization (CF) was 15750.0% in 2024 against a maximum downside of 121.31% in 2024.
• Year by year, Depreciation & Amortization (CF) stood at $146000.0 in 2021, then jumped by 210.27% to $453000.0 in 2022, then slumped by 99.56% to $2000.0 in 2023, then surged by 15750.0% to $317000.0 in 2024.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $317000.0, $260.0, and -$65.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.